T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016

T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016
Published Jul 13, 2016
48 pages — Published Jul 13, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016, provides in depth analysis on T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted pipeline therapeutics.

The report provides comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
- The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
- Identify the use of d

  
Source:
Document ID
GMDHC0384TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Overview61
Therapeutics Development74
  T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Stage of Development71
  T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Therapy Area81
  T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Indication92
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Products under Development by Companies132
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Companies Involved in Therapeutics Development214
  Atox Bio Ltd.211
  Bristol-Myers Squibb Company221
  OSE Immunotherapeutics231
  TheraMAB LLC241
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Drug Profiles2510
  AB-103 Drug Profile253
  FR-104 Drug Profile283
  lulizumab pegol Drug Profile311
  MF-280 Drug Profile321
  TAB-08 Drug Profile332
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Dormant Projects351
T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) Featured News &Press Releases3611
  Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections361
  Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)361
  Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control371
  Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104381
  Feb 12, 2015: Two major scientific articles validate Effimune s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system381
  Dec 25, 2014: TheraMAB presents new clinical data on theralizumab (TAB08) at Nature Biotechnology391
  Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority401
  Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections411
  Jan 14, 2014: TheraMAB announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis411
  Apr 09, 2013: Atox Bio Publishes Data Demonstrating Broad Therapeutic Effect Of Flagship Product In Treating Flesh Eating Bacteria421
  Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial431
  Sep 10, 2012: Atox Bio s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections441
  Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia441
  Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections451
  May 12, 2011: Atox Bio Completes Phase I clinical study Of AB103 For Severe Bacterial Infections And Sepsis461
Appendix472
  Methodology471
  Coverage471
  Secondary Research471
  Primary Research471
  Expert Panel Validation471
  Contact Us471
  Disclaimer481

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Specific-Surface-Glycoprotein-CD28-TP44-or-CD28-Pipeline-Review-H2-2016-2088-16191>
  
APA:
Global Markets Direct - Market Research. (2016). T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/T-Cell-Specific-Surface-Glycoprotein-CD28-TP44-or-CD28-Pipeline-Review-H2-2016-2088-16191>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.